Clinical Laserthermia Systems

RUMC has safely treated ten patients within the investigator initiated study using the TRANBERG® Thermal Therapy System with ThermoguideTM Workstation that is fully integrated with the MR-scanner and robotic system of the clinic. CLS and RUMC have agreed to continue the collaboration and have extended the study with an additional 5 patients to be treated with MR-guided focal laser ablation (FLA) using a freehand transperineal access approach. From this new group, the first patient has now been treated.

“All patients in the initial phase of the study have been technically successfully treated and we now started to investigate if we can achieve the same results using a different access path to reach the target. With tissue temperatures and tumor ablation monitored on images acquired from our MRI scanner -in near real-time- by CLS Thermoguide Workstation, the FLA procedures are done in a safe and relatively fast manner” said Jurgen Fütterer, Professor at Radboud University Medical Center and Principal Investigator.

“We are delighted that Radboud University Medical Center in Nijmegen, a very prominent European center in diagnosis and treatment of prostate cancer, has agreed to extend the investigator initiated study using our TRANBERG system for MR guided FLA. Their vast experience in focal therapy ensures another serious assessment of practical feasibility and safety of laser ablation, now using an alternative access approach. The outcome of this assessment may lead to a faster and easier adoption of TRANBERG laser ablation worldwide,” says Dan J. Mogren, CEO of Clinical Laserthermia Systems AB.”

The information was submitted for publication, through the agency of the contact person set out below on 20 Aug 2023.

For more information, please contact:


Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0)705 90 11 40
E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: clinicallaser.se